XML 127 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
shares in Thousands
1 Months Ended 12 Months Ended
Mar. 10, 2021
USD ($)
Jun. 30, 2021
shares
Dec. 31, 2023
USD ($)
sourceOfRevenue
tranche
reporting_unit
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Concentration Risk [Line Items]          
Number of sources of revenue | sourceOfRevenue     4    
Number of days to take exam     21 days    
Advertising costs     $ 52,969,000 $ 48,111,000 $ 42,964,000
Volunteer program, one-time payment to contributors $ 4,220,000        
Volunteer program, fees paid $ 526,000        
Compensation expense     $ 95,221,000 73,820,000 40,804,000
Number of reporting units | reporting_unit     1    
Impairment     $ 0 0 0
Research and development          
Concentration Risk [Line Items]          
Compensation expense     45,119,000 26,373,000 9,298,000
Sales and marketing          
Concentration Risk [Line Items]          
Compensation expense     3,908,000 2,540,000 881,000
General and administrative          
Concentration Risk [Line Items]          
Compensation expense     $ 46,139,000 44,869,000 30,617,000
RSUs outstanding          
Concentration Risk [Line Items]          
Number of vesting requirements | tranche     2    
Vesting period (in years)     4 years    
Compensation expense         2,035,000
Equity instruments other than options, grants in period (in shares) | shares     873    
RSUs outstanding | Research and development          
Concentration Risk [Line Items]          
Compensation expense         1,332,000
RSUs outstanding | Sales and marketing          
Concentration Risk [Line Items]          
Compensation expense         210,000
RSUs outstanding | General and administrative          
Concentration Risk [Line Items]          
Compensation expense         493,000
Founder awards where performance has been met          
Concentration Risk [Line Items]          
Compensation expense     $ 26,622,000 $ 30,997,000 $ 16,463,000
Founder awards where performance has been met | Founders          
Concentration Risk [Line Items]          
Equity instruments other than options, grants in period (in shares) | shares   1,800      
Number of tranches | tranche     10    
Capitalized Software          
Concentration Risk [Line Items]          
Estimated useful life (in years)     3 years    
Accounts Receivable | Customer Concentration Risk | Apple          
Concentration Risk [Line Items]          
Concentration risk (in percent)     65.20% 56.20%  
Accounts Receivable | Customer Concentration Risk | Google          
Concentration Risk [Line Items]          
Concentration risk (in percent)     20.70% 27.50%  
Accounts Receivable | Customer Concentration Risk | Stripe          
Concentration Risk [Line Items]          
Concentration risk (in percent)     10.70%    
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Apple          
Concentration Risk [Line Items]          
Concentration risk (in percent)     58.50% 54.20% 50.50%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Google          
Concentration Risk [Line Items]          
Concentration risk (in percent)     25.60% 28.10% 29.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Stripe          
Concentration Risk [Line Items]          
Concentration risk (in percent)     12.10%   10.10%